Contact
Diagnostics
About Abbott
i-STAT Registration
i-STAT Login
Customer Home
Partners Home
DISTRIBUTION HOME
Employees Home
REPAIR MANUAL
COMPLETE PROFILE
DASHBOARD
My Account
Worldwide

Global point of care

Afinion™ 2 System for reliable point-of-care testing

Highly Accurate, Quick, and Easy to Use for Diagnosis and Monitoring of Diabetes and Comorbidities

Improve the way you diagnose diabetes and comorbidities, monitor your patients, and manage their care. The Afinion™ point-of-care system delivers highly accurate results in minutes, in your office, without delays.

image
image
image

Make every minute count

Patients with diabetes need prompt diagnosis along with ongoing monitoring and care, and the AfinionTM 2 System is ideal for point-of-care testing (POCT). With its compact size and the range of tests it performs, it’s ideal for POCT in various settings—from physician offices and clinics to community health centers, retirement homes, emergency rooms and hospital outpatient clinics. In 3 easy steps, using a fingerstick-sized sample, you can get accurate results for HbA1c, lipids, and albumin/creatinine ratio (ACR).

Reliability, precision, and speed—proven in the field

The Afinion™ 2 Analyser is the product of continual innovation and refinement, since 2005. The result is enhanced precision: every Afinion 2 System is factory calibrated and released in accordance with stringent specifications. Regarding HbA1c testing quality assurance, for instance, the reliability of the Afinion™ 2 Analyser is demonstrated by meeting all SKUP (Scandinavian Evaluation of Laboratory Equipment for Primary Health Care) quality goals.1

Download a guide on the accuracy and precision of Afinion™ HbA1c. 

Download PDF
afinion afinion afinion
To find out more about how Afinion™ can transform your consultations, contact a member of our team today.

Improve practice efficiency with point-of-care testing

Incorporating POCT can allow for immediate therapy discussions, better patient outcomes, and enhanced clinic efficiencies. Studies2-5 show that testing in the office can increase efficiency by:

  • Avoiding separate lab visits, where patients can be lost to follow-up
  • Reducing the number of patient follow-up visits
  • Limiting the number of venous draws
  • Reducing administrative tasks—e.g. ordering lab tests and sending patient letters—which frees staff time 
afinion afinion afinion

Point-of-care

clock icon clock icon clock icon

30 minutes

  • Streamlined and efficient with no patients lost in the process
  • Better patient understanding
  • Better clinician/patient relationship
  • Better control of cardiovascular risk
lab icon lab icon lab icon

Central Lab

calendar icon calendar icon calendar icon

Days

  • Many steps can take several days with multiple visits, calls, and follow-ups
  • Patient can get ‘lost’ along the way
  • Inconvenient for the patient and provider
  • Extra work for the practice
blue image
blue image
Testimonial Testimonial Testimonial

“Testing ACR, lipids, and HbA1c in real time using a reliable and accurate point-of-care test is essential. It means I can make treatment decisions based on the latest and most accurate information.”

– Prof. Med. Bernd Schultes, Endocrinologist/Diabetologist
   St. Gallen, Switzerland
blue image
blue image

Provide Lipid and ACR POCT for CVD prediction and management

Diabetes is a complex disease that requires regular monitoring and care. People with diabetes are 2–3 times more likely to have cardiovascular disease (CVD).6 According to international guidelines, lipids and albumin/creatinine ratio (ACR) should be monitored annually.7-8 ACR is known to be a strong predictor for CVD.6,9

The Afinion™ Lipid Panel produces results in 7-8 minutes for total cholesterol (Chol), high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides (Trig), non-HDL, and Chol/HDL ratio. It is certified and accurate to CRMLN standards.10

ACR screening and monitoring are vital at the point of care

Since diabetic kidney disease (DKD) is such a serious complication of diabetes, patients’ albumin/creatinine ratio (ACR) should be monitored annually.7,8  A study of type 2 diabetes patients identified 29.3% of patients with DKD, but only 7.8% had this in their medical history.11 As highlighted recently ACR screening rates are extremely low in both diabetes (35%) and hypertension (4%) patients within 2 years.12 This is in contrast to the increasing number of effective therapies to prevent chronic kidney disease-related complications.

Download a guide on the accuracy and precision of Afinion™ HbA1c. 

Download PDF
infographic infographic infographic

DID YOU KNOW...

An annual assessment of the ACR value in patients with diabetes, as recommended by the guidelines, may positively affect the diagnosis of diabetic kidney disease and subsequently allow better management of patients with diabetes.

–  Schultes B, et al. 202113
DOWNLOAD THE STUDY

References

  1. SKUP. Report from the evaluation SKUP/2021/126. Afinion 2 Analyzer (Abbott Diagnostics Technologies AS), a system for measurement of HbA1c. www.skup.org (accessed 1. Jan 2022).
  2. El-Osta A, Woringer M, Pizzo E, et al. Does use of point-of-care testing improve cost-effectiveness of the NHS Health Check programme in the primary care setting: A cost-minimisation analysis. BMJ Open. 2017;7(8):e015494. 
  3. Patzer KH, Ardjomand P, Göhring K, et al. Implementation of HbA1c point of care testing in 3 German medical practices: impact on workflow and physician, staff, and patient satisfaction. J Diabetes Sci Technol. 2018;12(3):687-694.
  4. Lewandrowski EL, Yeh S, Baron J, et al. Implementation of point-of-care testing in a general internal medicine practice: A confirmation study. Clin Chim Acta. 2017;473:71-74.
  5. Crocker JB, Lee-Lewandrowski E, Lewandrowski N, et al. Implementation of point-of-care testing in an ambulatory practice of an academic medical center. Am J Clin Pathol. 2014;142(5):640-646.
  6. International Diabetes Federation. IDF Diabetes Atlas. 8th ed. 2017.
  7. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal 2019
  8. American Diabetes Association. Standards of medical care in diabetes—2022. Diabetes Care
  9. Matsushita K et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 2015;3: 514–25
  10. Centers for Disease Control and Prevention. CRMLN (Cholesterol Reference Method Laboratory Network): List of Certified Manufacturers. Accessed February 25, 2022. https://www.cdc.gov/labstandards/crmln_certified_manufacturers.html
  11. Brugnara L, Novials A, Ortega R, et al. Clinical characteristics, complications and management of patients with type 2 diabetes with and without diabetic kidney disease (DKD): A comparison of data from a clinical database. Endocrinol Diabetes Nutr (Engl Ed). 2018;65(1):30-38.
  12. Shin JI et al. Albuminuria Testing in Hypertension and Diabetes. An Individual-Participant Data Meta-Analysis in a Global Consortium. Hypertension 2021; 1042-1052
  13. Schultes B, Emmerich S, Kistler AD, et al. Impact of albumin-to-creatinine ratio point-of-care testing on the diagnosis and management of diabetic kidney disease. J Diabetes Sci Technol. 2021;19322968211054520. doi: 10.1177/19322968211054520

©2025 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.

Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy. Photos displayed are for illustrative purposes only. Any person depicted in such photographs is a model. GDPR Statement.

Not all products are available in all regions. Check with your local representative for availability in specific markets. For in vitro diagnostic use only. For i-STAT test cartridge information and intended use, refer to individual product pages or the cartridge information (CTI/IFU) in the i-STAT Support area.

Abbott - A Leader in Rapid Point-of-Care Diagnostics.